Content deleted Content added
Updating {{drugbox}} (changes to verified fields - updated 'KEGG_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs) |
No edit summary |
||
(37 intermediate revisions by 24 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 460779257 |
||
| IUPAC_name = 3-(4-bromophenyl)- |
| IUPAC_name = (3''S'')-3-(4-bromophenyl)-''N'',''N''-dimethyl-3-pyridin-2-yl-propan-1-amine |
||
| image = Dexbrompheniramine.svg |
| image = Dexbrompheniramine.svg |
||
| width = 222 |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = Drixoril, Conex, Dixaphedrine |
||
| Drugs.com = {{drugs.com| |
| Drugs.com = {{drugs.com|MTM|dexbrompheniramine}} |
||
| MedlinePlus = |
| MedlinePlus = |
||
| |
| pregnancy_US = C |
||
| legal_US = OTC |
| legal_US = OTC |
||
| legal_CA = OTC |
|||
| legal_status = [[Over-the-counter drug|OTC]]<small>([[Canada]])</small> |
|||
| routes_of_administration = |
| routes_of_administration = Oral |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
Line 21: | Line 24: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 7588 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 132-21-8 |
| CAS_number = 132-21-8 |
||
Line 29: | Line 32: | ||
| PubChem = 16960 |
| PubChem = 16960 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = DB00405 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 16068 |
| ChemSpiderID = 16068 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = 75T64B71RP |
| UNII = 75T64B71RP |
||
| ChEBI_Ref = {{ebicite| |
| ChEBI_Ref = {{ebicite|correct|EBI}} |
||
| ChEBI = 59269 |
| ChEBI = 59269 |
||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
Line 40: | Line 43: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=16 | H=19 | Br=1 | N=2 |
| C=16 | H=19 | Br=1 | N=2 |
||
| molecular_weight = 319.24 g/mol |
|||
| smiles = Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C |
| smiles = Brc1ccc(cc1)[C@@H](c2ncccc2)CCN(C)C |
||
| InChI = 1/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1 |
|||
| InChIKey = ZDIGNSYAACHWNL-HNNXBMFYBC |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1 |
| StdInChI = 1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1 |
||
Line 51: | Line 51: | ||
}} |
}} |
||
'''Dexbrompheniramine''' |
'''Dexbrompheniramine''' is an [[antihistamine]] with [[anticholinergic]] properties<ref>{{cite journal | vauthors = Löfkvist T | title = A comparative evaluation of oral decongestants in the treatment of vasomotor rhinitis | journal = The Journal of International Medical Research | volume = 6 | issue = 1 | pages = 56–60 | year = 1978 | pmid = 627306 | doi = 10.1177/030006057800600110 | s2cid = 39205584 }}</ref> used to treat [[allergy|allergic]] conditions such as [[hay fever]] or [[urticaria]]. It is the pharmacologically active dextrorotatory isomer of [[brompheniramine]]. It was formerly marketed in combination with [[pseudoephedrine]] under the name [[Drixoral]] in the US and Canada. It is an alkylamine antihistamine. |
||
Dexbrompheniramine is a first generation antihistamine that reduces the effects of the [[neurotransmitter]] [[histamine]] in the body; sneezing, itching, watery eyes, and runny nose. |
|||
== See also == |
|||
* [[Drixoral]] |
|||
* [[Brompheniramine]] |
|||
* [[Chlorpheniramine]] |
|||
* [[Dexchlorpheniramine]] |
|||
* [[Pheniramine]] |
|||
== |
== Interactions == |
||
MAO inhibitors within 14 days. MAO inhibitors include isocarboxazid, linezolid, phenelzine, rasagiline, selegiline, and tranylcypromine. |
|||
⚫ | |||
Drinking alcohol can increase side effects of dexbrompheniramine. |
|||
==References== |
|||
⚫ | |||
==External links== |
|||
*{{Commonscatinline}} |
|||
{{Antihistamines}} |
|||
{{Cholinergics}} |
{{Cholinergics}} |
||
{{Histaminergics}} |
{{Histaminergics}} |
||
⚫ | |||
⚫ | |||
[[Category:Pyridines]] |
|||
[[Category:Amines]] |
[[Category:Amines]] |
||
[[Category:Enantiopure drugs]] |
[[Category:Enantiopure drugs]] |
||
⚫ | |||
[[Category:Bromobenzene derivatives]] |
|||
⚫ | |||
{{respiratory-system-drug-stub}} |
|||
[[th:เดกซ์บรอมเฟนิรามีน]] |
|||
{{stereochemistry-stub}} |
|||
{{Amine-stub}} |
Revision as of 02:32, 15 April 2024
Clinical data | |
---|---|
Trade names | Drixoril, Conex, Dixaphedrine |
AHFS/Drugs.com | Multum Consumer Information |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 25 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.595 |
Chemical and physical data | |
Formula | C16H19BrN2 |
Molar mass | 319.246 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Dexbrompheniramine is an antihistamine with anticholinergic properties[1] used to treat allergic conditions such as hay fever or urticaria. It is the pharmacologically active dextrorotatory isomer of brompheniramine. It was formerly marketed in combination with pseudoephedrine under the name Drixoral in the US and Canada. It is an alkylamine antihistamine.
Dexbrompheniramine is a first generation antihistamine that reduces the effects of the neurotransmitter histamine in the body; sneezing, itching, watery eyes, and runny nose.
Interactions
MAO inhibitors within 14 days. MAO inhibitors include isocarboxazid, linezolid, phenelzine, rasagiline, selegiline, and tranylcypromine.
Drinking alcohol can increase side effects of dexbrompheniramine.
References
External links
- Media related to Dexbrompheniramine at Wikimedia Commons